Prevalence, etiology, and characteristics of patients with type-2 acute myocardial infarction  by Schmidt, Marcia Moura et al.
Rev Bras Cardiol Invasiva. 2015;23(2):119-123
Original Article
Prevalence, etiology, and characteristics of patients with type-2 acute myocardial 
infarction
Marcia Moura Schmidt, Alexandre Schaan de Quadros, Eduarda Schütz Martinelli,  
Carlos Antonio Mascia Gottschall*
Instituto de Cardiologia, Fundação Universitária de Cardiologia, Porto Alegre, RS, Brazil
A B S T R A C T
Background: In clinical practice, type-1 (coronary thrombosis) and type-2 (imbalance between oxygen 
demand and supply) acute myocardial infarction (AMI) are not clearly differentiated. The aim of this study 
was to evaluate the prevalence and etiology of type-2 AMI and compare its profile with that of type-1 AMI.
Methods: Patients admitted with ST-segment elevation AMI (STEMI) < 12 hours of symptom onset, and 
referred for coronary angiography, from 2009 to 2013, were analyzed.
Results: There were 1,960 patients included; 1,817 were analyzed, of whom 1,786 (98.3%) had type-1 AMI, 
and 31 (1.7%), type-2. All patients with type-2 AMI showed no significant coronary lesions, and 36% of the 
cases had apical dyskinesia. Type-2 AMI patients had, in general, a clinical and laboratory profile that was 
similar to those with type-1, except for the younger age, lower levels of myocardial necrosis markers, higher 
probability of having pre-TIMI 3 flow and higher left ventricular ejection fraction. At 30 days, mortality (3.2 
vs. 9.0%; p = 0.23) and the occurrence of death, reinfarction, or need for target-vessel revascularization (3.2 
vs. 13.0%; p = 0.09) were numerically lower in type-2 AMI.
Conclusions: Few patients with STEMI were classified as type-2; they had structural abnormalities, isolated 
or associated with the absence of significant lesions; showed little difference regarding the clinical and 
laboratory profile, and similar clinical outcomes at 30 days, when compared to patients with type-1 AMI.
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Prevalência, etiologia e características dos pacientes com infarto agudo do 
miocárdio tipo 2
R E S U M O
Introdução: Na prática clínica, os tipos 1 (trombose coronariana) e 2 (desequilíbrio entre a demanda e oferta 
de oxigênio) de infarto agudo do miocárdio (IAM) não são claramente distinguidos. O objetivo deste estudo 
foi avaliar a prevalência e a etiologia do IAM tipo 2, e comparar seu perfil com o do tipo 1.
Métodos: Foram analisados pacientes admitidos com IAM com supradesnivelamento do segmento ST 
(IAMCST) com < 12 horas, encaminhados para coronariografia, no período de 2009 a 2013. 
Resultados: Foram incluídos 1.960 pacientes, sendo 1.817 analisados, dos quais 1.786 (98,3%) com IAM 
tipo 1 e 31 (1,7%) do tipo de 2. Todos os pacientes com IAM tipo 2 apresentaram coronárias sem lesões 
significativas e, em 36% dos casos, discinesia apical. Os pacientes com IAM tipo 2 apresentaram, em geral, 
perfil clínico e laboratorial semelhante aos do tipo 1, com exceção da idade mais jovem, menores níveis de 
marcadores de necrose miocárdica, maior probabilidade de apresentarem fluxo TIMI 3 pré e maior fração 
de ejeção do ventrículo esquerdo. Aos 30 dias, a mortalidade (3,2 vs. 9,0%; p = 0,23) e a ocorrência de morte, 
reinfarto ou necessidade de revascularização do vaso-alvo (3,2 vs. 13,0%; p = 0,09) foram numericamente 
menores no IAM tipo 2.
Conclusões: Uma pequena fração de pacientes com IAMCST foi classificada como de tipo 2; exibiram anormalidades 
estruturais isoladas ou associadas à ausência de lesões significativas; mostraram poucas diferenças no perfil 
clínico e laboratorial, e desfechos clínicos semelhantes aos 30 dias, comparados aos pacientes com IAM tipo 1.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
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Introduction
Data from the Department of Informatics of the Unified Health 
System (DATASUS) 2013 show that acute myocardial infarction 
(AMI) was the main cause of death from heart disease in Brazil, with 
an increase of 48% observed between 1996 and 2011.1 If this trend 
persists, it is expected that AMI will become the main isolated cause 
of death by 2020.2
The universal definition jointly developed by the European Socie-
ty of Cardiology (ESC), American College of Cardiology Foundation 
(ACCF), American Heart Association (AHA), and World Heart Federa-
tion (WHF) subdivides AMI into five types.3,4 Type-1 AMI is a sponta-
neous event, resulting from coronary thrombosis, which results, in 
turn, from disruption, fracture, or erosion of the atherosclerotic pla-
que.5,6 The imbalance between oxygen demand and supply characte-
rizes type-2 AMI, which occurs in several conditions not associated 
with atherosclerotic plaque events. This imbalance can occur due to 
endothelial dysfunction, coronary vasospasm, coronary embolism, 
tachyarrhythmias and bradyarrhythmias, anemia, respiratory failu-
re, hypotension, and hypertension, with or without left ventricular 
hypertrophy. The other types include type-3 AMI, which is defined 
when patients suffer cardiac death, with symptoms suggestive of 
myocardial ischemia, accompanied by presumed new ischemic elec-
trocardiographic changes or new left bundle branch block, but wi-
thout available biomarker values. Type-4A is associated with 
percutaneous coronary intervention, and type 4B occurs in the pre-
sence of stent thrombosis. Type-5 characterizes the AMI associated 
with coronary artery bypass surgery.
In clinical practice, type-1 and type-2 AMI are not clearly diffe-
rentiated,7 and the electrocardiographic and biochemical characte-
ristics can be similar.8,9 Thus, the aim of this study was to evaluate 
the prevalence and etiology of type-2 AMI, compare the risk factors, 
clinical and laboratory characteristics, and outcomes of these pa-
tients with those of type-1, in a cohort of patients undergoing coro-
nary angiography for ST-segment elevation AMI (STEMI) in a referral 
cardiology hospital.
Methods
All patients were prospectively and sequentially enrolled at the 
hospital emergency department with STEMI, with < 12 hours of 
symptom onset, and submitted to coronary angiography in the pe-
riod from December 2009 to December 2013. The exclusion criteria 
included the patient's refusal to participate the study and age < 18 
years. The project was approved by the local research ethics com-
mittee. All patients or their family members signed an informed 
consent. The initial interview with the patient, carried out upon ar-
rival at the hospital emergency department, included the recording 
of demographic data, risk factors for ischemic heart disease, and cli-
nical presentation of the event.
STEMI was defined by electrocardiographic abnormalities (pre-
sence of new, or presumably new, ST-segment elevation > 0.1 mV in 
two or more contiguous leads), clinical presentation consistent 
with acute ischemia, and increase in myocardial necrosis markers 
(myocardial isoenzyme of creatine kinase - CK-MB with at least 
one value above the 99th percentile upper reference limit or, in the 
absence of CK-MB, total CK greater than twice the  upper limit of 
normal, or troponin elevation) within the 24 hours of symptom 
onset.10 Hypertension, diabetes mellitus, and dyslipidemia were 
classified according to the Guidelines of the Brazilian Society of 
Cardiology.11-13 The criterion used for family history of coronary 
artery disease (CAD) was the occurrence of AMI in first-degree 
male relatives younger than 55 years or in females younger than 
65 years.14
Medications used in the initial patient care consisted of acetylsali-
cylic acid, loading dose of 300 mg, and clopidogrel 300 to 600 mg, 
administered immediately after the patient's arrival in the emergen-
cy room. Unfractionated heparin at a dose of 70 to 100 IU/kg was 
used in the emergency or cath lab room.
Angiographic evaluations were performed using a previously va-
lidated digital electronic system. The number of vessels with lesions 
> 50%, the culprit vessel, and the presence of coronary calcification 
were assessed. The AMI-type classification was performed after the 
angiography, by the interventionists, according to the previously 
mentioned criteria.3,4 All patients’ images and reports were reviewed 
to confirm type-2 AMI, and to assess other angiographic findings.
Patient follow-up was performed during hospital stay and after 
discharge, by telephone contact at 30 days.
Statistical analysis
Categorical variables were expressed as frequencies and per-
centages, and were compared with the Chi-squared test or Fisher's 
exact test. Quantitative variables were expressed as mean and 
standard deviation, or median and interquartile range, and compa-
red by analysis of variance (ANOVA) or the Tukey test for multiple 
comparisons, in the case of normal distribution, or the Kruskal-
-Wallis test for asymmetric distribution of variables. Data were 
analyzed using Statistical Package for the Social Sciences (SPSS) for 
Windows, version 19.0 (IBM Corp., Armonk, USA). The values consi-
dered significant were those with p < 0.05.
Results
During the described period, 1,960 patients were assessed and 
1,817 were included in this study: 1,786 (98.3%) with type-1 AMI and 
31 (1.7%) with type-2 AMI (Fig. 1).
All patients with type-2 AMI had coronaries with absence of or 
no significant lesions. Additional findings included apical dyskinesia 
in 35.5% of cases, coronary tortuosity and left ventricular hypertro-
phy in 32.3%, and 22.6% with normal coronary arteries. One case of 
intramyocardial bridge (3.2%),another of cardiomyopathy (3.2%), 
and a third of aortic stenosis (3.2%) were also observed (Fig. 2).
Patients with STEMI 
1,960
Type-4B AMI 
96
Type-5 AMI 
33
1,817 
patients included
Type-1 AMI 
1,786
Type-2 AMI 
31
Figure 1. Study flow chart. STEMI: ST-elevation myocardial infarction; AMI: acute 
myocardial infarction.
Type-3 AMI 
3
Type-4A AMI 
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Among the clinical findings, this study found patients who had 
used cocaine (n = 1), using oral contraceptives (n = 1), with anemia 
(n = 1), ventricular fibrillation (n = 1), respiratory disease (n = 2), 
seropositivity for the human immunodeficiency virus (HIV; n = 2), 
under acute psychological stress (n = 3), or with suspected myocar-
ditis (n = 3).
When comparing the groups, patients with type-2 AMI were 
younger (50.6 ± 10.9 years vs. 60.6 ± 11.7 years; p < 0.001), more fre-
quently had a family history of CAD (51.6% vs. 30.0%; p = 0.01), and 
had lower abdominal circumference (90 ± 10 cm vs. 97 ± 14 cm; 
p = 0.02). They also had lower values of myocardial necrosis markers, 
such as CK-MB (12 [7-35] mg/dL vs. 41 [17-81] mg/dL; p < 0.001) and 
ultrasensitive troponin T (902 [191–3,004] ng/mL vs. 2,460 [68–
6,029] ng/mL; p = 0.008). Although C reactive protein was numeri-
cally higher in patients with type-2 AMI, the difference was not 
signif icant (0.51 [0.21–5.44] mg/L vs. 0.42 [0.20–0.93] mg/L; 
p = 0.25). Regarding the lipid profile, a difference was found only in 
the total cholesterol, which was lower (176 ± 43 mg/L vs. 205 ± 55 
mg/dL; p = 0.02) in these patients (Table 1).
In Table 2, it can be observed that the group of patients with type-2 
AMI had fewer patients with single-vessel involvement (6.4% vs. 
48.7%; p < 0.001), higher probability of having pre-TIMI 3 flow (96.8% 
vs. 22.8%; p < 0.001) and pre-myocardial blush grade 3 (96.8% vs. 
15.6%; p < 0.001), as well as higher ejection fraction (64.3 ± 14.3% vs. 
52.8 ± 15.2%, p = 0.002). As for medications, patients with type-2 AMI 
received less glycoprotein IIb/IIIa inhibitors (6.4% vs. 31.3%; p = 0.003).
At 30 days of follow-up, patients with type-2 AMI had numeri-
cally lower mortality (3.2% vs. 9.0%; p = 0.23) and occurrence of dea-
th, reinfarction, and need for new revascularization of the target 
vessel (3.2% vs. 13.0%, p = 0.09) than type-1 AMI patients, but wi-
thout reaching statistical significance.
Discussion
The main findings of this study demonstrate risk profile, pre-
vious history, clinical presentation, and laboratory characteristics 
that are generally similar between patients with type-1 and type-2 
AMI, which confirms the difficulty in the differential diagnosis be-
tween such patients. Studies comparing angiographic data in type-
1 and type-2 AMI are scarce in the literature.7,9,15 The prevalence of 
type-2 AMI is quite controversial, ranging from 2 to 26%.16-18 Other 
studies show an AMI incidence of 2.8% in patients with normal co-
ronary arteries.19
Regarding the absence of a significant obstructive lesion, Kang et 
al.20 reported that approximately 4% of 8,500 patients with AMI 
showed normal coronary arteries, and that the clinical features, ou-
tcomes, and prognosis were similar to those of patients with lesions 
in one or two vessels. The difference in mortality was only observed 
for patients with three-vessel involvement. The present study obser-
ved a prevalence of approximately 2% of patients with type-2 AMI. 
Similar to the findings of Kang et al.20, the group of patients with Figure 2. Characteristic findings of 31 patients with type 2 acute myocardial infarction 
and normal coronary arteries. LV: left ventricle.
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Table 1
Clinical and laboratory characteristics.
Characteristics Type-2 AMI 
(n = 31)
Type-1 AMI 
(n = 1.786)
p-value
Age, years 50.6 ± 10.9 60.6 ± 11.7 < 0.001
Male gender, n (%) 18 (58.1) 1,244 (69.7) 0.11
Caucasians, n (%) 25 (80.6) 1,502 (84.1) 0.47
Arterial hypertension, n (%) 18 (58.1) 1,157 (64.8) 0.26
Dyslipidemia, n (%) 9 (29.0) 640 (35.8) 0.28
Diabetes mellitus, n (%) 4 (12.9) 434 (24.3) 0.10
Smoking, n (%) 10 (32.3) 751 (42.1) 0.10
Family history of CAD, n (%) 16 (51.6) 536 (30.0) 0.01
Previous AMI, n (%) 4 (12.9) 357 (20.0) 0.22
Previous PCI, n (%) 3 (9.7) 286 (16.0) 0.21
CHF, n (%) 3 (9.7) 93 (5.2) 0.23
Anterior AMI, n (%) 11 (35.5) 770 (43.1) 0.25
Killip 4, n (%) 1 (3.2) 112 (6.3) 0.40
Pain at presentation, n (%) 25 (80.6) 1,563 (87.5) 0.19
Weight, kg 71 ± 10 77 ± 14 0.04
Waist circumference, cm 90 ± 10 97 ± 14 0.02
DBP, mmHg 79 ± 18 82 ± 19 0.43
SBP, mmHg 133 ± 31 137 ± 53 0.75
Heart rate, bpm 78.6 ± 17.2 78.7 ± 20.2 0.91
Delta T, h 3.38 [1.56-6.58] 3.96 [1.99-6.52] 0.33
Total cholesterol, mg/dL 176 ± 43 205 ± 55 0.02
Creatinine, mg/dL 0.85 ± 0.35 1.14 ± 4.35 0.74
Glycemia, mg/dL 147 ± 82 170 ± 82 0.19
CRP, mg/L 0.51 [0.20-5.44] 0.42 [0.20-0.93] 0.25
Fibrinogen, mg/dL 280.5 ± 138.0 255.0 ± 87.8 0.21
CK, U/L 153 [49-325] 133 [58-409] 0.55
CK-MB peak, mg/dL 12 [7-35] 41 [17-81] < 0.001
Peak troponin T, ng/mL 902 [191-3,004] 2,460 [68-6,029] 0.008
AMI: acute myocardial infarction; CAD: coronary artery disease; PCI: percutaneous coronary intervention; CHF: congestive heart failure; DBP: diastolic blood pressure; SBP: systolic blood pressure; CRP: C reactive 
protein; CK: creatine-kinase; CK-MB: creatine kinase myocardial isoenzyme.
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type-2 AMI was younger, had a family history of CAD, and had lower 
waist circumference when compared to the type-1 patients.
In the present study, it was observed that, despite the absence of 
significant lesions, the patients had coronary tortuosity, left ventricu-
lar hypertrophy, and apical dyskinesia, among others. Macruz et al.21 
developed an index to determine the ratio between the length of the 
tortuous artery and its normal length, thereby defining coronary tor-
tuosity. Other studies used the index by Macruz et al., such as Bastos 
and Cunha,22 who found 17 isolated or associated abnormalities in pa-
tients with normal coronary arteries. Isolated tortuosity was found in 
19 patients among the 105 assessed patients; ventricular hypertro-
phy, together with tortuosity, was found in 24 patients, and intramyo-
cardial bridge in six patients, only to name a few findings. In the 
present cases, ventricular hypertrophy and tortuosity were found in 
ten patients, and intramyocardial bridge in only one.
Apical dyskinesia, which was found in a little more than one-
-third of the patients with type-2 AMI, is a characteristic compatible 
with Takotsubo syndrome, whose clinical presentation is chest pain, 
ST-segment elevation on the electrocardiogram, and increase in bio-
markers, simulating an acute coronary syndrome, but with normal 
coronary arteries,23,24 with or without ventricular dysfunction. Ab-
sence of significant obstructive coronary artery disease and reversi-
bility of left ventricular contractility dysfunction are the important 
aspects for this diagnosis.25-27 Perhaps, due to the possible inclusion of 
these patients in the type-2 AMI sample, a higher ejection fraction 
was obtained in this group, contrary to the findings of Saaby et al.,17 
but corroborating those by Collste et al.,28 who also found patients 
with typical characteristics of Takotsubo in their study.
Coronary spasm may result in ST-segment elevation, although it 
is often associated with ST-segment depression, indicating subendo-
cardial myocardial ischemia. Coronary vasospasm is associated with 
several arrhythmias, including sinus bradycardia, total atrioventri-
cular block, paroxysmal atrial fibrillation, ventricular tachycardia, 
ventricular fibrillation, and extrasystoles.29 The vasospasm may be 
precipitated by stress, magnesium deficiency, consumption of al-
cohol, and drugs such as cocaine – conditions found in some of the 
present study’s patients.
The elevation of troponin in patients with normal coronary arte-
ries can occur due to tachyarrhythmias, left ventricular hypertro-
phy, and coronary vasospasm, being relatively common in patients 
with sepsis or systemic inflammation.30 It can also occur due to 
other non-ischemic conditions, such as myocarditis and pericarditis. 
In patients with HIV, a condition found in two of the patients, T-tro-
ponin elevation may occur due to flow-related complications, such 
as hypercoagulability, endothelial dysfunction, and vasculitis.
The present study observed, at a lower prevalence among the cli-
nical findings, that approximately 10% of patients had suspected 
myocarditis. Of the 176 patients in the study by Collste et al.,28 7% 
showed typical signs of myocarditis when submitted to cardiac 
magnetic resonance assessment.
Regarding the clinical outcomes, Alpert et al.15 described a higher 
mortality in patients with type-2 AMI when compared to their type-1 
group. However, they included several patients with anemia, several 
types of arrhythmias, acute pulmonary edema, and respiratory failu-
re, i.e., more severe conditions that may have increased mortality in 
this group of patients. However, De Ferrari et al.31 reported that death 
or AMI was less frequent among patients without significant obstruc-
tive disease (2.2%), in opposition to those with obstructive disease 
(13.3%) at 30 days of follow-up. This difference was also observed in 
the present study, although it did not reach statistical significance.
Although there are few studies on type-2 AMI,15 the present au-
thors have observed some discrepancies in these studies, which may 
be due to the interpretation of classification criteria and the diversi-
ty of conditions included in that classification.15,30,31 According to 
Canty et al.,32 different pathologies can cause imbalance in myocar-
dial oxygen supply and demand. Further studies are needed to assist 
in the identification and improvement of this classification,8,9,15,29,30 
and even to question it, since type-2 AMI is not recognized in the 
International Classification of Diseases (ICD).8
Study limitations
One of the limitations was associated to the inclusion of a pre-se-
lected population of patients with STEMI, which favors the occur-
rence of type-1 AMI and thus, this study may not reflect the true 
epidemiology of type-2 AMI.
Another limitation lies in the fact that patients with type 2 AMI have 
not been evaluated by intracoronary vascular ultrasound. This imaging 
modality, often detect hidden lesions in patients with angiographically 
"normal" coronary artery disease, and the unavailability of these re-
sults may have caused misclassification.
Conclusions
In this study, few patients with ST-segment elevation myocar-
dial infarction were classified as type-2 infarction; had isolated 
Table 2
Angiographic characteristics and medications used in the first 24 hours.
Characteristics Type-2 AMI 
(n = 31)
Type-1 AMI 
(n = 1.786)
p-value
Femoral access, n (%) 20 (64.5) 1,118 (63) 0.53
Lesion in 1 vessel, n (%) 2 (6.4) 869 (48.7) < 0.001
Calcified lesion, n (%) 1 (3.2) 229 (12.8) 0.52
Pre-TIMI 3 flow, n (%) 30 (96.8) 407 (22.8) < 0.001
Pre-myocardial blush 3, n (%) 30 (96.8) 279 (15.6) < 0.001
LV ejection fraction, % 64.3 ± 14.3 52.8 ± 15.2 0.002
GP IIb/IIIa inhibitors, n (%) 2 (6.4) 559 (31.3) 0.003
Clopidogrel 600 mg, n (%) 25 (80.6) 1,516 (84.9) 0.10
ASA, n (%) 30 (96.8) 1,746 (97.8) 0.40
Betablocker, n (%) 19 (61.3) 1,221 (68.4) 0.24
ACEI, n (%) 18 (58.1) 1,221 (68.4) 0.14
ARA II, n (%) 1 (3.2) 47 (2.6) 0.57
Nitrate, n (%) 4 (12.9) 310 (17.4) 0.35
Continuous heparin, n (%) 16 (51.6) 1,027 (57.5) 0.30
Enoxaparin, n (%) 3 (9.7) 60 (3.4) 0.09
Diuretic, n (%) 5 (16.1) 115 (6.4) 0.05
Statin, n (%) 25 (80.6) 1,520 (85.1) 0.28
Nitroglycerine, n (%) 5 (16.1) 261 (14.6) 0.49
Dopamine/noradrenaline, n (%) 1 (3.2) 139 (7.8) 0.29
TIMI: Thrombolysis In Myocardial Infarction; LV: left ventricle; GP: glycoprotein; ASA: acetylsalicylic acid; ACEI: angiotensin-converting enzyme inhibitors; ARA II: angiotensin-II receptor antagonists.
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structural abnormalities or associated with the absence of signifi-
cant lesions at the coronary angiography; showed few differences 
in the clinical and laboratory profile, when compared to patients 
with type-1 myocardial infarction; and had similar clinical outco-
mes at 30 days.
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